A Docking Study of Newly Found Natural Neuraminidase Inhibitor: Erystagallin A

다국어 초록 (Multilingual Abstract)

It's a threat for the public health that H1N1 (Influenza virus A) causes disease and transmits among humans. WHO (world health organization) declared that the infections caused by the new strain had reached pandemic proportions. The approved neuraminidase inhibitors (Zanamivir and Oseltamivir) and related investigative drug (BCX-1812) are potent, specific inhibitors of influenza A and B viruses. These drugs are highly effective to prevent influenza A and B infections. Early therapeutic use reduces illness duration and respiratory complications. Recently, we found one of the potent inhibitor of erystagallin A ($IC_{50}$ of 2.04 ${\mu}M$) for neuraminidase target, this inhibitor shows most similar structure to its natural substrate, sialic acid. Therefore, we chose 1l7f to get the receptor structure for docking study among many crystal structures. A docking study has been performed in Surflex-Dock module in SYBYL 8.1. In the present study, we attempt to compare the docking studies of pterocarpin and erystagallin A with neuraminidase receptor structure. In the previous report, the methoxy group of pterocarpin had H-bonding with Arg residues. The present docking results for erystagallin A showed the backbone of hydroxyl group shows significant H-bonding interactions with Arg152 and Arg292. The results showed that erystagallin A interacts more favorably with distinctive binding site rather than original active site. Therefore, we tried to reveal plausible binding mode and important amino acid for this inhibitor using docking and site id search calculations of Sybyl. The results obtained from this work may be utilized to design novel inhibitors for neuraminidase.

참고문헌 (Reference)

1 A. N. Jain, "Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity- Based Search Engine" 46 : 499-, 2003

2 G. Alagona, "Structure and Dynamics of the Hydrogen-Bond Network around (R,R)-Pterocarpins with Biological Activity in Aqueous Solution" 109 : 16918-, 2005

3 A. A. Ghate, "Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design" 258 : 320-, 1998

4 A. N. Jain, "Scoring functions for protein-ligand docking" 7 : 407-, 2006

5 W. J. Brouillette, "Pyrrolidinobenzoic Acid Inhibitors of Influenza Virus Neuraminidase: Modifications of Essential Pyrrolidinone Ring Substituents" 11 : 2739-, 2003

6 Y. B. Ryu, "Pterocarpins and flavanones from Sophora flavescens displaying potent neuraminidase inhibition" 18 : 6046-, 2008

7 P. H. Nguyen, "Prenylated pterocarpans as bacterial neuraminidase inhibitors" 18 : 3335-3344, 2010

8 G. Alagona, "Conformational Landscape of (R,R)-Pterocarpins with Biological Activity in Vacuo and in Aqueous Solution (PCM and/ or Water Clusters)" 110 : 647-, 2006

9 C. M. W. Ho, "Cavity search: An algorithm for the isolation and display of cavity-like binding regions" 4 : 337-, 1990

10 SYBYL 8.1 TI, "1699 South Hanley Rd., St. Louis, Missouri, 63144, USA"